Pfizer sets out major revamp

Pfizer said it would reorganise into three units, separating its consumer healthcare business that the US drugmaker has been trying to sell since last year.

The news comes a day after the company decided to defer drug price increases for no more than six months, following criticism from US President Donald Trump for raising list prices of some medicines.